Mounting evidence suggests that FOXM1 overexpression contributes to chemoresistance in ovarian cancer [5], while it has been well established that survivin confers chemoresistance on cancer cells in general by increasing the threshold for chemotherapy-induced apoptosis [22,23,24,25]. Here, BIRC5 is linked to ovarian carcinoma.